Medpace Holdings ($MEDP (-6,36%) ) reports Q4 2024 earnings:
Q4 2024:
Sales: 536.6M vs. 535.0M expected (+0.3%) 🟡
EBITDA: 133.5M vs. 115.2M expected (+15.89%) 🚀
EBIT: 125.4M vs. 107.9M expected (+16.22%) 🚀
Net Income: 117.0M vs. 96.1M expected (+21.75%) 🚀
FY2024:
Sales: 2109.0M vs. 2107.0M expected (+0.09%) 🟡
EBITDA: 480.2M vs. 460.4M expected (+4.3%) 🟢
EBIT: 446.9M vs. 431.3M expected (+3.62%) 🟢
Net Income: 404.4M vs. 383.7M expected (+5.39%) 🟢
CapEx: 36.5M vs. 42.0M expected (-13.1%)
FCF: 572.3M vs. 472.1M expected (+21.22%) 🚀
Outlook for FY2025:
Sales: 2160.0M vs. 2238.0M expected (-3.49%) 🔴
EBITDA: 479.0M vs. 482.1M expected (-0.64%) 🟡
Net Income: 390.0M vs. 403.4M expected (-3.32%) 🔴
Backlog / Sales sinkt das erste Mal unter 1 (auf 0.99). Aber der Abschwung verlangsamt sich deutlich. Ausblick liegt unter Erwartungen
